Hovedmålet var at demonstrere, at degarelix er effektivt i forhold til at nå og opretholde testosteron suppression på under 0, 5 ng/ ml i løbet af 12 måneders behandling.
The primary objective was to demonstrate that degarelix is effective with respect to achieving and maintaining testosterone suppression to below 0.5 ng/ ml, during 12 months of treatment.